Friedreich’s Ataxia

Friedreich's ataxia is caused by too little of a protein called frataxin, so a major goal is to restore it at the source. This review from a leading center surveys the cutting-edge genetic and cellular therapies now in development, including gene therapies that add a working copy of the FXN gene and cell-based approaches. The authors weigh what each strategy has shown so far and the hurdles ahead. No such therapy is proven yet, but the pipeline aiming to change the disease course is growing quickly.

Omaveloxolone (Skyclarys) is the first approved treatment for Friedreich's ataxia and works by switching on a cellular defense pathway (Nrf2). Because the drug can affect metabolism, this real-world study tracked cholesterol and other blood fats over one year in patients taking it. Measuring these lipid changes helps clarify this side of the drug's effects and informs monitoring. Practical safety information like this helps doctors and families use the medicine well while the search for additional treatments continues.

Heart disease is the leading cause of death in Friedreich's ataxia, yet its mechanisms are not fully understood. Researchers grew heart cells from patients' own stem cells and compared them with gene-corrected versions in which the faulty GAA repeat had been removed using CRISPR. The frataxin-deficient cells showed clear heart-muscle dysfunction and widespread changes in gene activity, which the correction reversed. The model gives researchers a human system to study FRDA cardiomyopathy and to test treatments aimed at protecting the heart.

This is one of the first clinical trials of gene therapy for the heart disease of Friedreich's ataxia. The therapy, AAVrh.10hFXN, uses a harmless virus given by vein to deliver a working copy of the FXN gene, aiming to restore frataxin in heart muscle, which the disease damages and which is the main cause of death. The study assessed safety and early signs of benefit. It is an early-stage, non-randomized trial, but it marks an important step toward treating FRDA cardiomyopathy at its genetic root.

Friedreich's ataxia usually occurs when a child inherits an over-expanded GAA repeat in the FXN gene from both parents. This study traced where these disease-causing expansions come from, identifying smaller precursor alleles (protomutations) that can grow into full expansions across generations. The findings help explain why FRDA is common in some populations and rare in others. Understanding how these expansions arise and persist sharpens genetic counseling for families and deepens the picture of the disease's origins.

Omaveloxolone was approved after a trial showed it slowed worsening on a standard Friedreich's ataxia rating scale (mFARS). This analysis pooled results from the available studies, including the original trial, its long-term extension, and real-world observations, covering 248 patients, and compared the combined outcome against the disease's expected natural decline. Bringing the evidence together helps clarify how much benefit the drug offers over time and supports doctors and families weighing treatment. It also highlights the value of longer-term data.

Because Friedreich's ataxia stems from a shortage of frataxin, one strategy is to deliver the protein into the cells that lack it. Researchers engineered a version of frataxin able to be secreted and to penetrate cells and reach the mitochondria where it is needed, delivered using blood stem cells carrying the gene. In laboratory and animal models of FRDA, the approach corrected biochemical defects and protected cells. It is an early, preclinical proof of concept for a frataxin-replacement therapy that would need testing in people.

This Cochrane review, a respected form of independent evidence synthesis, examined the medicines studied for Friedreich's ataxia to see which are supported by reliable trial evidence. It weighed drugs aimed at slowing the disease or easing its symptoms, including the approved treatment omaveloxolone, and judged the strength and limitations of the data. Reviews like this give patients and clinicians a clear, unbiased summary of what current medications can and cannot do, and point to where better trials are still needed.

Vatiquinone is an oral drug that blocks an enzyme (15-lipoxygenase) involved in oxidative stress and inflammation, aiming to protect cells in Friedreich's ataxia. This phase 3 study is designed to confirm vatiquinone's effect on the main measures of FRDA progression over the long term. Vatiquinone is one of the treatments furthest along in development for the neurological symptoms of the disease. It is not yet open for enrollment. Ask your care team whether a trial like this may become an option.

SGT-212 is an experimental gene therapy for Friedreich's ataxia designed to deliver a working copy of the FXN gene so cells can make frataxin, the protein patients lack. This first-in-human study gives it in two ways at once, directly into a deep brain structure (the dentate nucleus) and by vein, to reach both the nervous system and the heart. The early-stage trial is testing safety and the right dose in adults with FRDA. Ask your care team whether you might be eligible.

Omaveloxolone (Skyclarys) is approved for Friedreich's ataxia in people aged 16 and older, but not yet for younger patients. This phase 3 study is testing how well it works and how safe it is in children and teenagers with FRDA, comparing it with placebo. Extending an approved treatment to younger ages matters because the disease often begins in childhood. The study is recruiting at many sites. Families can ask their care team whether taking part makes sense.

Heart muscle disease (cardiomyopathy) is a major and life-threatening part of Friedreich's ataxia, yet its course varies from person to person. CLARITY-FA is an observational study following people who have FRDA-associated cardiomyopathy to document how it develops over time. It does not test a drug, but the detailed heart data it gathers help researchers understand the condition and design and interpret trials of heart-directed therapies, including gene therapies. Ask an FRDA center whether joining could be right for you.

CTI-1601 (nomlabofusp) is an investigational therapy that aims to replace the missing frataxin directly, delivering the protein into cells by injection under the skin. This open-label phase 2 study evaluates the safety and effects of long-term daily dosing in children, adolescents, and adults with Friedreich's ataxia, including those who took part in earlier CTI-1601 studies. Because FRDA is caused by a frataxin shortage, restoring the protein is a direct approach. Ask your care team whether you might be eligible.

This trial is testing AAVrh.10hFXN, a gene therapy for the heart disease of Friedreich's ataxia. Given by vein, it uses a harmless virus to deliver a working copy of the FXN gene so heart muscle can make frataxin, which the disease depletes. The early-phase study evaluates safety and preliminary effectiveness at escalating doses, with a short course of a steroid (prednisone). Because cardiomyopathy is the main cause of death in FRDA, treating it at the genetic root is a key goal. Ask your care team about eligibility.

UNIFIED is a large, global observational study run by the Friedreich Ataxia Global Clinical Consortium. It follows people with FRDA over time at many centers, carefully tracking how the disease progresses. It does not test a treatment, but the standardized data it collects are essential for understanding the disease and for developing and testing safe, effective therapies, and it helps connect patients with the research network. Ask an FRDA clinic near you whether taking part is possible.

DT-216P2 is an experimental medicine designed to switch the silenced FXN gene back on so cells can make more frataxin, addressing the root cause of Friedreich's ataxia. This early trial gives repeated, increasing doses to adults with FRDA to evaluate safety, tolerability, and how the drug behaves in the body. Because the FXN gene in FRDA is turned down rather than missing, reactivating it is a promising strategy. Ask your care team whether a study like this could be an option for you.